Sumitomo Pharma Co., Ltd. (formerly Dainippon Sumitomo Pharma)
隶属于 Sumitomo Chemical Co., Ltd.
Japanese multinational pharmaceutical company focused on oncology, psychiatry, neurology, women's health and urological diseases; formed through the 2005 merger of Dainippon Pharmaceutical and Sumitomo Pharmaceuticals. Listed on the Tokyo Stock Exchange (4506).
相关临床试验
50
8 进行中
药物批准
17
批准总数
监管机构
1
监管机构数
成立时间
2005
进行中（未招募）
8
16.0%
已完成
29
58.0%
招募中
10
20.0%
终止
3
6.0%
- Definium Therapeutics' DT120 ODT met its primary and all key secondary endpoints in the Phase 3 Panorama trial of 245 adults with generalized anxiety disorder. - The 100-microgram dose produced a 9.8-point HAM-A reduction versus 4.7 points for placebo at Week 12, a 5.1-point placebo-adjusted difference (p<0.0001, Cohen's d=0.64). - Panorama is the second positive Phase 3 GAD study for DT120 ODT and the third positive late-stage readout overall, following Voyage in GAD and Emerge in MDD. - Definium has scheduled a pre-NDA meeting with the FDA for Q4 2026 and plans to submit its New Drug Application in the first half of 2027.
- Over 30,000 people in the U.S. live with cystic fibrosis, with rising diagnosed prevalence driving demand for targeted therapies and precision medicine approaches. - CFTR modulator therapies have dramatically transformed treatment by targeting underlying CFTR gene mutations, improving lung function, life expectancy, and reducing hospital admissions. - Gene therapy and CRISPR-based gene-editing technologies are emerging as potential long-term or permanent solutions, though they remain in development. - High drug costs and limited treatment options for rare CFTR mutations continue to pose significant barriers to patient access globally.
- A Japanese health ministry panel has conditionally endorsed two groundbreaking iPS cell-derived treatments, marking the world's first commercial products based on induced pluripotent stem cell technology. - Sumitomo Pharma's AMCHEPRY for Parkinson's disease showed motor function improvements in four of six clinical trial patients, while Cuorips's RiHEART cardiac patches improved symptoms in all eight heart failure patients tested. - Both therapies received conditional approval with a mandatory seven-year evaluation period, with formal ministerial approval expected in early March and potential patient availability by summer 2024. - Nobel laureate Shinya Yamanaka, who pioneered iPS cell technology, emphasized the need for continued safety and effectiveness verification to establish these treatments as standard medicine.
- The Commercial Court of Lyon has approved Poxel's recovery plan and ended the judicial reorganization proceedings that began on August 5, 2025. - The recovery plan includes establishing new partnerships for Imeglimin commercialization in Asia, promoting PXL770 for ADPKD, and leveraging PXL065 for HCM. - Financial restructuring involves €5 million equity line from IRIS, €3.75 million bond borrowings from IPF, and capital increases to strengthen the company's position. - The plan enables Poxel to continue developing its metabolic disease portfolio while settling outstanding liabilities and optimizing cost structure.
- Poxel SA, a clinical-stage biopharmaceutical company developing treatments for metabolic diseases, has entered judicial reorganization proceedings following a court hearing on August 5, 2025. - The company will continue operations during a six-month observation period while exploring options including a continuation plan to maintain its drug development activities. - Poxel's pipeline includes PXL065 for MASH treatment, which met its primary endpoint in the Phase 2 DESTINY-1 trial, and PXL770 for rare metabolic disorders. - Trading of Poxel shares on Euronext Paris resumed on August 11, 2025, following the court's decision to initiate the reorganization process.
- Scientists have launched the first-ever library of 25 vaccine-enhancing adjuvants hosted by the UK's MHRA to boost vaccine performance against epidemic and pandemic threats including mpox, COVID-19, Ebola, and future Disease X. - The $2.5 million CEPI-funded project will serve as a matchmaking service, allowing vaccine developers to request up to five adjuvant samples from late 2025 to identify optimal vaccine-adjuvant combinations through preclinical testing. - The library aims to support the 100 Days Mission by rapidly identifying top-performing vaccine-adjuvant pairings during disease outbreaks, potentially containing viral spread before reaching pandemic proportions. - Adjuvants from 14 leading research institutes and medical companies worldwide will be available on a non-exclusive basis, with developers encouraged to publish findings in open-access publications for global benefit.
- Syndax Pharmaceuticals' REVUFORJ (revumenib) became the first FDA-approved menin inhibitor in November 2024, targeting KMT2A-rearranged acute leukemia patients aged one year and older. - Multiple companies including Kura Oncology, Sumitomo Pharma, and Johnson & Johnson are advancing next-generation menin inhibitors through clinical trials, with ziftomenib receiving breakthrough therapy designation for NPM1-mutant AML. - The market faces challenges from highly specific patient populations defined by genetic mutations and potential clinical resistance mechanisms, but shows promise for expansion into solid tumors and combination therapies. - Strategic partnerships and AI-driven drug development platforms are accelerating innovation, with companies exploring applications beyond hematologic cancers into diabetes and solid tumor indications.
- Knight Therapeutics has entered into exclusive licensing agreements with Sumitomo Pharma to commercialize MYFEMBREE, ORGOVYX, and vibegron in Canada for an upfront payment of C$25.4 million. - The acquired portfolio generated C$11.2 million in revenue for the year ended March 2025, with MYFEMBREE representing the first oral treatment for uterine fibroids and endometriosis in Canada. - The transaction aligns with Sumitomo's strategy to focus on U.S. operations and pipeline development in oncology, regenerative medicine, and cell therapy. - Knight expects the products to be highly synergistic with its existing Canadian women's health and urology portfolio, including IMVEXXY, BIJUVA, and TRELSTAR.
- Poxel's PXL065, a deuterium-stabilized R-enantiomer of pioglitazone, demonstrated significant benefits in preventing pathological myocardial remodeling in a mouse model of hypertrophic cardiomyopathy. - The preclinical study showed PXL065 prevented hypertrophy and fibrosis in the heart, supporting its potential as a disease-modifying treatment for both symptomatic and asymptomatic HCM patients. - Results will be presented at the European Society of Cardiology Congress on September 1st, 2025, highlighting the compound's dual mechanism targeting mitochondrial dysfunction and oxidative stress. - The findings address a significant unmet medical need in HCM, which affects approximately 1 in 500 adults and currently has limited effective treatment options.
• The schizophrenia treatment landscape is expanding with over 60 drugs in active development, driven by increased R&D and innovative therapies. • Key players like Sumitomo Pharma, Boehringer Ingelheim, and Reviva Pharmaceuticals are advancing novel antipsychotics and personalized medicine approaches. • Recent progress includes positive Phase III trial results for brilaroxazine and LY03020's IND approval in China, signaling potential new treatment options. • COBENFY, a first-in-class muscarinic agonist, received FDA approval, marking a significant advancement in schizophrenia treatment after 35 years.
